Accessing treatments for hepatitis C through the Hepatitis C January 1, 1986 — July 1, 1990 Class Actions Settlement: What you need to know
If you are a patient who received tainted blood or blood products and a registered claimant of the Hepatitis C (HCV) 1986-1990 Class Actions Settlement (www.hepc8690.ca), now is a good time to speak to your doctor about new treatments for HCV. Treatment has progressed significantly, and now may be the right time for you to seek a cure.
Recently, new HCV therapies have been approved by Health Canada that shorten the duration of treatment, achieve a cure rate of more than 90%, minimize side effects compared to past treatments, and are interferon free. To complement your commitment to treatment, there are new resources in Canada that can help you start your journey.
Many companies that make and sell hepatitis C medications have programs to support patients throughout treatment.These programs offer assistance by providing drugs upfront to the 86-90 claimants through their specialty pharmacy. Once the 86-90 plan issues the reimbursement cheques to the patients for their treatment, they, in turn, must reimburse the pharmacy directly.
Typically, these programs are designed to provide a wide range of customized services including reimbursement assistance, education and ongoing disease management support. They will not only support health care professionals but people living with hepatitis C throughout their treatment journey to achieve a possible cure. This assistance will cover the entire treatment regimen that your doctor will prescribe including drugs from one or more pharmaceutical companies.
To enrol in one of these programs, speak to your doctor or your nurse or contact the programs directly for more information:
|AbbVie Care™||Holkira™ Pak (paritaprevir/ritonavir/ ombitasvir tablets; dasabuvir tablets)
Maviret™ (glecaprevir/pibrentasvir tablets)
|CLAIRE Patient Support Program||Daklinza™ (daclatasvir)
|Galexos™: BioAdvance® Patient Support Program||Galexos™ (simeprevir)||1-855-512-3740|
|Gilead Momentum HCV Support Program™||Sovaldi® (sofosbuvir)
Harvoni® (ledipasvir and sofosbuvir tablet)
Epclusa™ (sofosbuvir and velpatasvir in a single tablet)
|Merck Care™Hepatitis C Program||Zepatier™
(elbasvir and grazoprevir)
Accessing treatments for hepatitis C through the Hepatitis C January 1, 1986 — July 1, 1990 Class Actions Settlement:
What you need to know
Information brochure targeted at patients who received tainted blood or blood products and who are registered claimants of the Hepatitis C 1986-1990 Class Actions Settlement.
This brochure provides information on accessing treatments for hepatitis C as well as support programs offered by pharmaceutical companies.